A Phase 1 Trial of IMA203CD8, a PRAME-directed TCR T-cell Therapy in PRAME-positive Solid Tumors

ESMO Immuno-Oncology Congress 2025

December 10-12, 2025, London, United Kingdom

Busse, et. al

Read more